-
AlphaVac is AngioDynamics' mechanical thrombectomy device for removing blood clots from large veins, including pulmonary embolism (PE). Already FDA-cleared (initial 2021, PE-specific April 2024, expanded VTE Nov 2025) and CE-marked in Europe (May 2024). The APEX-AV trial published in JSCAI (Jan 2025) showed 35.5% clot burden reduction, and the RECOVER-AV long-term outcomes study began enrollment in June 2025. It competes in a ~$1.9B thrombectomy device market growing ~7% CAGR, against Inari Medical's FlowTriever (acquired by Stryker for $4.9B in Dec 2025) and Penumbra's Indigo. AlphaVac is one of several growth drivers in AngioDynamics' Med Tech segment (FY2026: $150M, +18.4% YoY) but is not the company's primary near-term catalyst — that distinction belongs to the NanoKnife oncology platform.
Explore drug → -
NanoKnife is AngioDynamics' irreversible electroporation (IRE) ablation system — a medical device, not a drug — that uses electrical pulses to non-thermally destroy tumors while preserving surrounding healthy tissue. It received FDA 510(k) clearance in December 2024 for prostate tissue ablation in intermediate-risk prostate cancer based on the PRESERVE pivotal trial. Named to TIME's 2025 Best Inventions list. NanoKnife is now in early commercial launch, with Medicare coverage effective July 2026. In FY2026 Q4, NanoKnife generated $11.8M in revenue (+64.5% YoY), and the company guided FY2027 net sales of $336M-$341M. The device also has an FDA IDE approval to explore treatment of benign prostatic hyperplasia (BPH) under the RELIEF feasibility study. Competition includes HIFU, cryotherapy, and other focal therapy modalities for prostate cancer.
Explore drug →
Eftilagimod alfa (efti) is Immutep's only clinical-stage asset — a first-in-class LAG-3 agonist that activates the immune system against cancer. The drug suffered a major blow in March 2026 when the Phase III TACTI-004 trial in first-line NSCLC was discontinued for futility, causing an ~85% stock crash. However, the drug maintains promising pipelines in head and neck cancer (positive TACTI-003 Phase IIb with FDA backing for a path forward), metastatic breast cancer (ongoing AIPAC-003 Phase II/III), and soft tissue sarcoma (Phase II success, FDA Orphan Drug Designation). A root cause analysis of the NSCLC failure is due in Q3 2026 and will be a critical catalyst. The company has ~$99M in cash and a Dr. Reddy's partnership ($20M upfront) providing some financial runway.
SP001 (IBI355) is a third-generation anti-CD40L antibody that Spero Therapeutics in-licensed from Innovent Biologics on July 14, 2026, in a deal valued up to ~$1.1B plus tiered royalties. The asset has completed Phase 1 and is Phase 2-ready. Spero plans to initiate a Phase 2 trial in IgG4-related disease (a rare autoimmune disorder) in Q2 2027, while Innovent runs a separate Phase 2 in Sjögren's disease in China. To fund development, Spero simultaneously announced a $105M non-dilutive royalty financing from Healthcare Royalty, backed by its recently FDA-approved antibiotic Utebzi (tebipenem). The deal marks a strategic pivot from infectious disease into immunology for Spero. However, SP001 carries significant development risk, faces competition from other anti-CD40L programs, and the milestone obligations are massive relative to Spero's ~$126M market cap.
PMN310 is ProMIS Neurosciences' lead (and only clinical-stage) asset — a monoclonal antibody designed to selectively target toxic amyloid-beta oligomers in Alzheimer's disease. Phase 1a data showed a favorable safety profile and dose-dependent target engagement in CSF. The Phase 1b PRECISE-AD trial (144 patients enrolled, 3 doses vs. placebo over 12 months) completed enrollment in December 2025. A blinded 6-month interim analysis is expected imminently (noted as "coming weeks" in a July 14, 2026 AAIC press release), with final topline data by end of 2026. The FDA granted Fast Track designation in July 2025. The company raised ~$75M upfront (up to $175M with warrants) via PIPE in January 2026 to fund development. Analyst consensus is Strong Buy (9:1 bullish) with a mean price target of ~$32, implying ~150% upside from ~$12.80. Key risks: Phase 1b interim results could disappoint, the Alzheimer's market is intensely competitive with approved plaque-directed antibodies, and ProMIS has no revenue or other clinical-stage programs to fall back on.
ERAS-0015 is Erasca's lead asset — an oral pan-RAS molecular glue currently in Phase 1 trials for RAS-mutant solid tumors. Early data shows compelling response rates in hard-to-treat KRAS-mutant NSCLC (62% unconfirmed ORR) and pancreatic cancer (57% at the recommended dose), which compare favorably on a cross-trial basis to Revolution Medicines' RMC-6236. However, the program is shadowed by a securities class action (alleging misleading comparator claims), a patent-infringement dispute with Revolution Medicines, and a Phase 1 patient death. Erasca has $408.5M cash (runway into H2 2028), a Merck collaboration for a Keytruda combination, and plans to initiate registration-enabling trials in H1 2027.
DIABIT-IS X is a generic version of sitagliptin (Merck's Januvia), a well-established DPP-4 inhibitor for type 2 diabetes. Cosmos Health (NASDAQ: COSM) acquired the European license and rights for ~$3.5M as part of a 10-drug generic portfolio in December 2023, positioning itself as a first mover after Januvia's European patent expiration. On July 13, 2026, Cosmos signed a five-year distribution partnership with Libytec Pharmaceutical to commercialize the drug in Greece, with the drug accessible through the national health insurance system. As a generic of an off-patent blockbuster (Januvia + Janumet generated $4.5B in 2022 sales), DIABIT-IS X has a clear market path but faces intense generic competition and pricing erosion. Cosmos Health is a small-cap ($15-20M market cap) diversified healthcare group with multiple revenue streams — this one drug is a modest growth contributor, not a needle-mover on its own.
OCU400 is Ocugen's lead modifier gene therapy candidate for retinitis pigmentosa (RP), a group of inherited retinal diseases affecting ~110,000 people in the US and 1.6M globally. Unlike the only approved RP gene therapy (Luxturna, which works on only one gene mutation), OCU400 takes a gene-agnostic approach via the NR2E3 master regulator, potentially treating many of the ~100 known RP-causing mutations. Phase 1/2 data showed durable safety and vision improvement over 2-3 years. Phase 3 liMeliGhT trial enrollment is complete (n=140) with topline data due Q1 2027; a rolling BLA submission is targeted for Q3 2026. Recent $130M convertible note financing extends cash runway into 2028. The stock has strong analyst support (9 Buy/1 Hold, mean PT ~$11.43) and Q1 2026 saw broad institutional accumulation (Millennium, Jane Street, Bank of America, Point72, RTW Investments all increased positions).
Bempikibart (ADX-914) is Q32 Bio's lead — and after the ADX-097 sale, essentially sole late-stage — asset. It is a first-in-class anti-IL-7Rα antibody in Phase 2 development for alopecia areata (AA). On July 13, 2026, the company reported positive 36-week Part B data from the SIGNAL-AA trial showing a 35.3% mean reduction in the primary SALT severity score, 40% SALT-20 response rate, and a clean safety profile — driving a ~60% single-day stock surge. A prior Phase 2a trial in atopic dermatitis (SIGNAL-AD) failed its primary endpoint in December 2024. The company now plans a registration-directed (Phase 3) program beginning in H1 2027. Bempikibart competes against approved JAK inhibitors (Pfizer's Litfulo, Lilly's Olumiant) and other emerging biologics in the AA market, but its novel mechanism and clean safety profile (no black-box warnings like the JAK class) could differentiate it. The ~$190M market-cap company will need additional capital to fund the pivotal program.
VY1706 is Voyager Therapeutics' wholly-owned tau-silencing gene therapy for Alzheimer's disease and the first tau-targeted gene therapy to receive FDA IND clearance (June 2026). It uses the company's proprietary TRACER capsid to deliver an siRNA across the blood-brain barrier via a single IV dose. Preclinical data showed up to 73% tau mRNA knockdown and good tolerability. First-in-human dosing is expected in H2 2026. The drug is early-stage with significant binary risk, but the target (tau) is gaining traction in Alzheimer's research, and the gene therapy approach could be paradigm-shifting if successful. Analyst consensus is Strong Buy with ~219% implied upside, but the company trades at ~$3.22, reflecting the high risk of early-stage CNS drug development.
Pelareorep is Oncolytics Biotech's sole asset — a first-in-class oncolytic reovirus being developed as an intravenous immunotherapy for multiple hard-to-treat cancers. Phase 2 data have shown promising survival signals: near-doubling of median OS in HR+/HER2- breast cancer (21 vs 10.8 months), a 62% ORR in 1L pancreatic cancer (vs ~25% historical), and durable responses in 3rd-line anal cancer where no FDA-approved therapies exist. The FDA has granted Fast Track designations for pancreatic and colorectal cancer, and the company has secured agency alignment on pivotal study designs for both pancreatic and anal cancer. However, pelareorep has not yet entered a pivotal Phase 3 study (trial launch expected H1 2026), and Oncolytics has limited cash (~$12.4M as of Q3 2025), creating dilution risk via a recently announced $75M ATM facility. The stock trades near $0.92 with a ~$105M market cap.
ART27.13 is Artelo Biosciences' lead drug candidate, a once-daily oral pill targeting cancer-related anorexia and cachexia (CACS) — a condition with no FDA-approved treatment affecting up to 80% of advanced cancer patients. Phase 2 interim data showed patients on the highest dose gained ~6% body weight over 12 weeks while placebo patients lost ~5%, with correlated gains in lean body mass. The company is also exploring ART27.13 in glaucoma (via a fully funded investigator-sponsored trial enrolling in Q2 2026), as a GLP-1 companion therapy for muscle preservation, and in preclinical models of chemotherapy-induced nerve pain. However, ARTL is a micro-cap with roughly $10M cash, has executed two reverse stock splits to maintain Nasdaq listing, underwent dilutive financing, and has zero analyst Buy ratings (3 Hold, 3 Sell/Strong Sell). The company is actively seeking a development partner to fund registration trials — making partnership news the key near-term catalyst.
EDG-7500 is Edgewise Therapeutics' lead cardiovascular asset — a novel oral cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM), a genetic heart disease affecting ~1 in 500 people. Positive 12-week Phase 2 data (June 16, 2026) showed broad clinical improvements across LVOT gradient, NT-proBNP biomarker, and symptom scores, with no patient experiencing LVEF drop below 50% — a clean safety profile that differentiates it from already-approved Camzyos (mavacamten, BMS) and Cytokinetics' aficamten. However, the stock fell ~10% on the readout as the efficacy magnitude disappointed relative to competitors. Edgewise recently sold its muscular dystrophy business to Servier for $1.55B upfront (+ up to $1.1B milestones), fully funding EDG-7500 through potential approval and repositioning the company as a pure-play cardiovascular biotech. Phase 3 starts in Q4 2026. The stock trades at ~$43.69 near its 52-week high, with analyst consensus 'Strong Buy' and mean price target ~$49.
MAT2203 is an oral, encochleated form of amphotericin B — a potent broad-spectrum antifungal typically only available intravenously. It received FDA QIDP, Fast Track, and Orphan Drug designations. The FDA agreed to a single Phase 3 registration trial (ORALTO), but the trial was never started after a licensing partnership fell through in October 2024. On July 13, 2026, Matinas BioPharma announced it is selling MAT2203 (along with its LNC platform) to private Azurity Pharmaceuticals for $4M upfront plus up to $17.5M in milestones, while simultaneously merging with GH Power to exit biotech entirely. For MTNB shareholders, MAT2203 has become a terminal asset being monetized for modest cash — the stock now tracks the reverse-merger closing, not the drug's clinical prospects.
ALTO-207 is a fixed-dose combination of pramipexole (dopamine agonist) and ondansetron (anti-emetic) being developed by Alto Neuroscience (NYSE: ANRO) for treatment-resistant depression (TRD). It was acquired from Chase Therapeutics in June 2025 for $1.75M upfront plus milestone payments up to $71.5M. A Phase 2a trial in 32 MDD patients showed strong efficacy signals (Cohen's d=1.67 on MADRS at week 6) with good tolerability. A Phase 2b potentially pivotal trial (~178 patients) began in April 2026, with topline data expected 2H 2027. The company has ~$244M cash (through 2029), strong analyst support (16 buy/strong-buy, mean PT $35.13 vs ~$26 currently), and recently announced an expanded Phase 3 monotherapy program. The main risk: Phase 2b data is >12 months away, and the stock has already rallied ~940% from its 52-week low, pricing in significant optimism.
Botensilimab is Agenus' lead asset — an Fc-enhanced anti-CTLA-4 antibody designed to outperform Yervoy (ipilimumab). It has shown durable responses in nine difficult-to-treat metastatic cancers, with notable 33-42% survival rates at 2-3 years in refractory MSS colorectal cancer, a population typically resistant to immunotherapy. However, the FDA rejected an accelerated approval pathway, requiring a full Phase 3 trial that began enrollment in April 2026. Agenus just announced a heavily dilutive ~$85M PIPE financing (July 13, 2026) to fund the Phase 3 trial. The stock trades near its 52-week low with high short interest (~14.4% of shares outstanding), reflecting skepticism about the long timeline and dilution.
KRSA-028 is a preclinical-stage brain-shuttled anti-amyloid beta monoclonal antibody for Alzheimer's disease, developed by Korsana Biosciences. Korsana is reverse-merging into Cyclerion Therapeutics (CYCN) in an all-stock deal backed by a $380M PIPE, giving the combined entity (to trade as KRSA) ~$475M in pro-forma cash and runway into 2029. The drug uses Korsana's proprietary THETA platform to cross the blood-brain barrier via transferrin receptors. Preclinical data suggest KRSA-028 has a >2.5x longer half-life in NHPs vs Roche's competing trontinemab and avoids reticulocyte depletion. However, the drug has no human data yet, the Alzheimer's amyloid space is crowded with approved drugs (Leqembi, Kisunla) and multiple later-stage competitors, and current CYCN shareholders face extreme dilution to ~1.1-1.5% ownership post-merger.
-
Rigosertib is an oncology drug that failed two Phase 3 trials in myelodysplastic syndromes (MDS) and has been effectively deprioritized by developer Traws Pharma (formerly Onconova Therapeutics). The company has pivoted to antiviral drugs (influenza, hantavirus, Ebola) and is now actively seeking a partner to take rigosertib forward in RDEB-associated squamous cell carcinoma, an ultra-rare skin cancer. Early data in 5 patients showed an 80% response rate, but this is a very small dataset. There is no near-term binary catalyst, no regulatory submission planned, and the stock has been battered by clinical holds on its lead antiviral program — not by rigosertib news. Both HC Wainwright and Ladenburg Thalmann downgraded TRAW from Buy to Neutral in June 2026.
Explore drug → -
Narazaciclib is an oral multi-kinase inhibitor targeting CDK4/6, CSF1R, and ARK5 that Traws Pharma inherited from the Onconova/Trawsfynydd merger. It completed Phase 1/2 dose escalation in low-grade endometrioid endometrial cancer (LGEEC) in Q2 2024, establishing an RP2D. However, Traws has since pivoted entirely to antivirals (influenza, COVID-19) and explicitly labels narazaciclib a "legacy" asset that it is seeking to out-license. The drug faces fierce competition from three marketed CDK4/6 inhibitors (Pfizer's Ibrance, Novartis' Kisqali, Lilly's Verzenio) with billion-dollar sales. Traws is a micro-cap (~$10M market cap) with a going-concern warning, heavy dilution (up to $5.6M ATM offering, plus recent $60M PIPE with dilutive warrants), and analysts have downgraded the stock. For a TRAW investor, narazaciclib is a negligible value driver — the stock's fate rests on the antiviral pipeline.
Explore drug → -
Tivoxavir marboxil is Traws Pharma's lead asset — an oral antiviral for influenza that works via the same cap-dependent endonuclease mechanism as Roche's approved Xofluza. Phase 1 data showed good safety and maintained drug levels above the efficacy threshold for over 23 days from a single dose. However, the program has hit dual regulatory walls: in February 2026 the FDA placed the IND on clinical hold over mutagenicity data concerns, and in June 2026 the UK MHRA issued a negative review that forced deferral of the planned Phase 2a human challenge trial — a trial tied to $20M in funding. The company is now developing backup drug candidates. Traws Pharma is financially distressed (~$10M market cap, ~$5M cash, going concern, $647M accumulated deficit), and both covering analysts (HC Wainwright, Ladenburg Thalmann) downgraded from Buy to Neutral in June 2026. With no hard catalyst date for clinical hold resolution, the drug offers no near-term binary event for investors.
Explore drug →
Risvutatug rezetecan (Ris-Rez) is GSK's investigational B7-H3-targeted antibody-drug conjugate, in-licensed from Hansoh Pharma (China) in Dec 2023 for $185M upfront. It has a novel mechanism pairing a B7-H3 antibody with a topoisomerase I inhibitor payload. On July 10, 2026, Hansoh announced positive Phase 3 (ARTEMIS-008) results in advanced/relapsed SCLC — the first positive Phase 3 overall survival data ever reported for a B7-H3 ADC. This validates the mechanism but was conducted only in China (Hansoh's territory). GSK's own global Phase 3 in SCLC began in Aug 2025 but won't read out until likely 2027-2028. The drug has FDA and Japan Orphan Drug Designations for SCLC. Outside SCLC, it's being explored in prostate, NSCLC, colorectal, head & neck, and GI cancers. GSK is also running combo trials with Summit's ivonescimab and Artios' alnodesertib. Peak sales estimates (ex-China) are $1-2B. For GSK (a ~$85B market cap pharma with $44.8B revenue), this is a promising mid-pipeline asset but not a make-or-break catalyst.
Bexobrutideg is Nurix Therapeutics' lead asset — a first-in-class oral BTK degrader showing promising Phase 1 data in heavily pretreated CLL (83% ORR, 22.1-month PFS). In June 2026, Roche partnered on the drug in a deal worth up to $2.3 billion ($700M upfront), providing deep validation, a 50/50 U.S. profit split, and diversified development into immunology and neurology. The drug faces head-to-head competition with Lilly's approved pirtobrutinib (Jaypirca) in an upcoming Phase 3 trial. The Roche deal transforms Nurix's financial runway (pro-forma ~$1.24B cash) but the stock has already re-rated significantly; future upside depends on clinical execution in pivotal trials.
-
TRYNGOLZA (olezarsen) is Ionis Pharmaceuticals' lead commercial drug — an FDA-approved antisense oligonucleotide targeting apoC-III to lower triglycerides. It was first approved in Dec 2024 for the ultra-rare condition FCS, generating ~$108M in its first year. The much bigger catalyst was the June 24, 2026 FDA approval for sHTG (severe hypertriglyceridemia), which addresses a U.S. population of over 3 million patients. Ionis dramatically cut the annual list price 93% from $595K to $40K to access this broader market. Management has raised peak sales estimates to >$3B. The drug now faces a commercial execution test and competition from Arrowhead's plozasiran (Redemplo), which targets the same mechanism via siRNA.
Explore drug → -
Eplontersen (branded Wainua in the US, Wainzua in the EU) is an FDA-approved antisense oligonucleotide from Ionis Pharmaceuticals (IONS) and partner AstraZeneca for treating hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). It generated $212M in global 2025 sales, with Ionis receiving $49M in royalties. The drug's pivotal Phase 3 CARDIO-TTRansform trial for the much larger ATTR cardiomyopathy (heart) indication failed its primary endpoint on July 9, 2026, causing IONS stock to drop ~20%. A prespecified monotherapy subgroup showed a nominally significant benefit, but the overall miss was a major setback that boosts competitor drugs from Alnylam (Amvuttra) and BridgeBio (Attruby). The approved hATTR-PN business continues, but the largest value-driving opportunity is now off the table.
Explore drug →
Wainua (eplontersen) is an FDA-approved antisense oligonucleotide for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), co-developed and commercialized by AstraZeneca and Ionis Pharmaceuticals. It generated $212M in global sales in 2025. However, on July 9, 2026, the pivotal CARDIO-TTRansform Phase 3 trial in the much larger ATTR cardiomyopathy (ATTR-CM) indication failed its primary endpoint of reducing cardiovascular mortality and recurrent CV events. This is a significant setback because ATTR-CM represents a blockbuster market already dominated by Pfizer's tafamidis (~$4B) and contested by BridgeBio's acoramidis and Alnylam's vutrisiran. For AstraZeneca ($587B cap), the impact is manageable; for Ionis (~$5B cap), it is a more severe blow to its growth narrative.
Semaglutide is the blockbuster GLP-1 drug behind Novo Nordisk's Ozempic, Wegovy, and Rybelsus — a class generating tens of billions in annual sales. Dr. Reddy's Laboratories (NYSE: RDY) was the first generic to enter the Canadian market (April 2026) and launched its own semaglutide injection and oral tablet (branded Obeda) in India. However, on July 9, 2026, Dr. Reddy's suspended production after detecting an API impurity, slashing its FY27 supply target from 12M to 6-7M pens and wiping ~$678M from its market cap. Semaglutide is a very large commercial opportunity for generic manufacturers as patents expire globally, but near-term execution risk at Dr. Reddy's is significant.
CardiolRx is a pharmaceutical-grade oral cannabidiol (CBD) solution being developed by Cardiol Therapeutics (CRDL) for inflammatory heart conditions. Its lead indication is recurrent pericarditis, where a Phase II study showed a 71% recurrence-free rate and symptom improvement, leading to an ongoing pivotal Phase III MAVERIC trial. Enrollment is at ~75% with topline data expected H2 2026. The drug also showed positive Phase II results in acute myocarditis (ARCHER trial). The company is a micro-cap (~$115M market cap) with CardiolRx as its sole late-stage asset, making the upcoming MAVERIC readout a binary event. Analyst consensus is Strong Buy with a mean target of ~$7.20, but significant equity dilution and the high-risk Phase III binary create a wide range of potential outcomes for the stock.
DA-1726 is MetaVia Inc.'s lead drug candidate — a GLP-1/glucagon dual agonist (a type of obesity treatment) currently in Phase 1 trials. Early data showed 9.1% mean weight loss at 48mg over 8 weeks, which is competitive with established drugs but was from a small, early-stage cohort. The company just completed dose titration on Part 3 (higher doses up to 64mg), with topline data due Q4 2026. MetaVia has a tiny ~$8M market cap, heavy dilution via an ATM offering, and faces overwhelming competition from Novo Nordisk, Eli Lilly, and Boehringer Ingelheim/Zealand Pharma whose survodutide just showed 16.6% weight loss in Phase 3. The stock is a binary bet on the Phase 1 readout — success could yield enormous percentage returns given the micro-cap, but the odds are long.
AXS-05 (Auvelity) is Axsome Therapeutics' lead commercial drug — an oral, fixed-dose combination of dextromethorphan and bupropion. Originally FDA-approved for major depressive disorder in August 2022, it became the first oral NMDA receptor antagonist and first new mechanism of action for MDD in over six decades. On April 30, 2026, the FDA significantly expanded the label to include agitation associated with Alzheimer's disease dementia — the first non-antipsychotic ever approved for that indication. Auvelity generated $507.1 million in U.S. net product sales in FY2025 (74% YoY growth), and management projects peak annual sales of at least $8 billion across both indications. The commercial launch for Alzheimer's agitation began in June 2026. The stock has rallied strongly (~155% from its 52-week low) on the approval and raised guidance, but as an already-approved drug with no new binary regulatory catalyst pending near-term, the next 12 months are about commercial execution rather than a binary event.
ImmuneSelect is Virax Biolabs' commercially available research-use-only (RUO) T-cell immune profiling product line — not a drug. Launched in April 2024, it includes ELISpot assay plates, peptide pools, and antibodies sold to academic and pharma researchers for immune monitoring. On July 9, 2026, Virax signed an exclusive multi-country supply agreement with Fosun Diagnostics covering six Southeast Asian markets, driving the stock up 100%+ in a single session. However, Virax remains a development-stage company with only $12K in FY2026 revenue, a $5M annual net loss, an accumulated deficit exceeding $24M, and a recent 1-for-25 reverse stock split to maintain Nasdaq listing. The product faces entrenched competition from established ELISpot/FluoroSpot suppliers, and the Fosun deal's financial terms (volume-based tiers with performance-linked exclusivity) have no disclosed minimums, making near-term revenue impact uncertain.